7-oxo-3,4-seco-5β-cholanetrioic acid-(3.4.24) | 62965-07-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7-oxo-3,4-seco-5β-cholanetrioic acid-(3.4.24)
• 英文别名: 7-Oxo-3,4-seco-5β-cholantrisaeure-(3.4.24)
• CAS: 62965-07-5
• 化学式: C₂₄H₃₆O₇
• 分子量: 436.546
• InChiKey: HVQWVXVXQDTAQP-VJSDRUSQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.09
• 重原子数：
  31.0
• 可旋转键数：
  8.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  128.97
• 氢给体数：
  3.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  7-oxo-3,4-seco-5β-cholanetrioic acid-(3.4.24) 在 盐酸 、 amalgamated zinc 、 硫酸 、 溶剂黄146 作用下， 生成 3.4-seco-5β-cholanetrioic acid-(3.4.24)-trimethyl ester
  参考文献：
  名称：

  Kaziro, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1929, vol. 185, p. 151,163

  摘要：

  DOI：
• 作为产物：
  描述：

  3,7-二酮-5Β-胆甾烷-24-酸 在 chromium(VI) oxide 、 溶剂黄146 作用下， 生成 7-oxo-3,4-seco-5β-cholanetrioic acid-(3.4.24)
  参考文献：
  名称：

  Windaus; Bohne; Schwarzkopf, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1924, vol. 140, p. 177,182

  摘要：

  DOI：

文献信息

• Serum leptin levels are not influenced by arginine and insulin infusion and by acute changes of GH
  作者：G. Radetti、C. Tinelli、C. Paganini、M. Draghi、D. Scarcella、E. Bozzola、G. Aimaretti、G. Rondini、L. Tatò

  DOI：10.1007/bf03345510

  日期：2002.10

  The aim of this study was to evaluate the relationship between GH and leptin in a group of short children and adolescents. Leptin and GH serum levels were measured before and during pharmacological stimulation tests (arginine and insulin) in a group of 45 children (30 male, 15 female), mean age 8.6+/-3.9 yr, affected by idiopathic isolated GH deficiency (GHD), and in a group of 27 children (115 male, 12 female), age 10.9 +/- 3.3 yr, with constitutional growth delay. Results showed that basal and peak leptin levels as well as the AUC were significantly higher in GHD patients compared to controls (p<0.05) and correlated with BMI SDS (p<0.0001) in GHD patients. No change in leptin serum levels was observed during either stimulation test. No correlation was found, however, between basal leptin serum levels and basal, peak and the AUC of GH during the tests. Moreover, no correlation was found between the acute changes of serum GH concentration during both stimulation tests and leptin serum levels. The results suggest that leptin and GH secretion is not correlated and that leptin serum levels mainly reflect the amount of fat tissue, which is higher in GHD patients.
• Windaus; van Schoor, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1926, vol. 157, p. 177,183
  作者：Windaus、van Schoor

  DOI：——

  日期：——
• Effects of sibutramine in non-dieting obese women
  作者：Adnan Gokcel、Y. Gumurdulu、H. Karakose、B. M. Karademir、R. Anarat

  DOI：10.1007/bf03343971

  日期：2002.2

  The aim of this study was to evaluate the effects of sibutramine on plasma leptin levels, body weight and glucose metabolism in non-dieting women. Fourteen healthy, non-diabetic, obese women were studied before treatment, after 1 week of placebo administration, and after a 2-week course of sibutramine (110 mg/day). At each of these stages, we assessed body composition, measured the levels of plasma leptin, C-peptide and various biochemical parameters, and also recorded plasma insulin and glucose levels during oral glucose tolerance tests. After 1 week of placebo treatment, there were no significant changes in any of the parameters. However, two weeks of 10 mg/day sibutramine dropped plasma leptin levels from a mean (+/-SE) of 48.84+/-4.54 to 42.84+/-4.74 ng/ml (p<0.04), reduced BMI from 39.36+/-2.01 to 38.57+/-1.93 kg/m(2) (p<0.002), and decreased insulin resistance (IR, as measured using the homeostasis model assessment of insulin resistance) from 5.59+/-0.85 to 3.66+/-0.43 (p<0.02). There was no correlation between the reduction in leptin concentration and the decrease in BMI, fat mass, percent body fat, IR, C-peptide, or the area under curve for glucose or insulin. There was also no correlation between the decrease in leptin levels and the increases that occurred in the insulin sensitivity index or the hepatic sensitivity index. The results showed that treatment with 10 mg/day sibutramine significantly reduces BMI, IR and leptin levels in non-dieting obese women. (C) 2002, Editrice Kurtis.